ストックスクリーナーアプリを入手
1.64
1.86%
0.03
アフターアワーズ：
1.64
Coherus Oncology Inc (CHRS) 最新ニュース
CHRS Should I Buy - Intellectia AI
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncolog - AD HOC NEWS
Coherus Oncology Q1 earnings call highlights - MSN
What Does The Future Hold For Coherus Oncology, Inc. (NASDAQ:CHRS)? These Analysts Have Been Cutting Their Estimates - 富途牛牛
CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook By Investing.com - Investing.com Australia
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook - Investing.com UK
Timothy Youngquist Trust amends 13G; holds 12.75M CHRS (NASDAQ: CHRS) - Stock Titan
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today - Yahoo Finance
Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives - Sahm
Maxim Group Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Coherus Oncology, Inc. (NASDAQ:CHRS) Q1 2026 Earnings Call Transcript - Insider Monkey
Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) - Seeking Alpha
Number of shareholders of Coherus Oncology, Inc. – MUN:8C5 - TradingView
Kura Oncology Q1 Earnings Call Highlights - inkl
Coherus Oncology (CHRS) Reports Q1 Earnings and Updates on LOQTO - GuruFocus
CHRS: Coherus Oncology, Inc.Interactive Chart - Zacks Investment Research
Coherus Oncology (CHRS) Reports Q1 2026 Earnings and Future Proj - GuruFocus
Coherus Oncology (CHRS) reports Q1 loss, lags revenue estimates - MSN
Coherus targets $15M quarterly LOQTORZI sales in 2026 while advancing midyear tagmokitug and casdozokitug readouts - MSN
Coherus Oncology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: St - GuruFocus
Coherus Oncology Q1 2026 Earnings Call Transcript - MarketBeat
Guggenheim initiates coverage of Coherus Oncology (CHRS) with buy recommendation - MSN
Earnings Call Summary | Coherus Oncology(CHRS.US) Q1 2026 Earnings Conference - Moomoo
Coherus Oncology Q1 Earnings Call Highlights - sharewise.com
CHRS: LOQTORZI sales surged 61% year-over-year, with robust pipeline progress and strengthened funding - TradingView
Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast By Investing.com - Investing.com South Africa
Is Coherus Oncology (CHRS) Overvalued After Q1 2026? GAAP EPS -$ - GuruFocus
CHRS Q1 2026 Earnings Transcript - The Globe and Mail
CHRS: LOQTORZI sales surged 61% year-over-year, with robust clinical and commercial momentum - TradingView
Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast - Investing.com Nigeria
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Q1 2026 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
Coherus Oncology (CHRS) boosts LOQTORZI sales and cash with Q1 2026 stock offering - Stock Titan
Coherus Oncology: Q1 Earnings Snapshot - WKYC
Coherus Oncology Q1 sales rise - TradingView
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
CHRS: LOQTORZI revenue surged 61% year-over-year as net losses narrowed and cash reserves remained strong - TradingView
Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M - Stock Titan
CHRS Initiated Coverage By Guggenheim -- Price Target Set at $12 - GuruFocus
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):